Welcome to ourQ3 Report 2020

September 25 was a historic day with the approval of filgotinib under the brand name Jyseleca® by both the Japanese and European authorities.

Financial highlights

Group revenues

€368.6 million

At a glance

Cash position

€5308.6 million

At a glance

Deferred income

€2789.2 million

At a glance

R&D expenditure

€398.1 million

At a glance

Letter from the management

We are excited to bring our first medicine to patients in Europe as we continue to focus on the discovery and development of novel therapies in inflammation and fibrosis. Onno van de Stolpe, CEO
Letter from the management